Published finding — does the expert body still believe it?
Pembrolizumab is associated with lower rates of grade 3-5 treatment-related adverse events (10.1–13.3%) compared with ipilimumab (19.9%) in patients with advanced melanoma.
TL;DR · AI-generated
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Author-implied confidence
90%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
96% → 96% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
· openalex W2152897456 · s2 0dac3ea8
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1063
Grade 3 or 4 treatment-related adverse events occur significantly more frequently with nivolumab plus ipilimumab (55.0%) than with nivolumab monotherapy (16.3%) or ipilimumab monotherapy (27.3%) in untreated metastatic melanoma patients.
0.1238
Pembrolizumab achieves an objective response rate of approximately 33% in advanced melanoma, compared with 11.9% for ipilimumab (P<0.001).
0.1396
Pembrolizumab (10 mg/kg every 2 weeks) improves 12-month overall survival to 74.1% versus 58.2% for ipilimumab (HR 0.63, P=0.0005) in patients with advanced melanoma.
0.1451
Pembrolizumab (10 mg/kg every 2 weeks) improves 6-month progression-free survival to 47.3% versus 26.5% for ipilimumab (HR 0.58, P<0.001) in patients with advanced melanoma.
0.1761
Pembrolizumab's PFS and OS benefit over ipilimumab in advanced melanoma will be maintained at longer follow-up beyond the median 7.9-month observation period reported in this trial.
0.1886
In previously untreated patients with unresectable stage III/IV melanoma, nivolumab plus ipilimumab achieves a median progression-free survival of 11.5 months versus 2.9 months with ipilimumab alone (HR 0.42, P<0.001).